doi: 10.1016/j.diabres.2019.107843 4 StrattonIMAdlerAINeilHAMatthewsDRManleySECullCAet al
GLP-1 Medications Are Different: Pharmaceutical GLP-1 medications are synthetic versions engineered to: Last much longer in your body (days instead of minutes) Resist breakdown by enzymes Maintain therapeutic levels continuously Produce stronger, sustained effects than natural GLP-1 Think of it this way: Natural GLP-1: Brief Im full signal during meals GLP-1 medications: Continuous youre satisfied, dont overeat signal all week Types of GLP-1 Medications: Pure GLP-1 Receptor Agonists: These activate only GLP-1 receptors: Semaglutide: Brand names: Wegovy (weight loss), Ozempic (diabetes) Dosing: Once weekly injection Average weight loss: 10-15% of body weight FDA approved: 2017 (Ozempic), 2021 (Wegovy) Liraglutide: Brand name: Saxenda (weight loss), Victoza (diabetes) Dosing: Daily injection Average weight loss: 5-8% of body weight Older, less effective than semaglutide Dulaglutide: Brand name: Trulicity Dosing: Once weekly injection Primarily for diabetes, not typically used for weight loss Dual GIP/GLP-1 Receptor Agonist: Tirzepatide: Brand names: Zepbound (weight loss), Mounjaro (diabetes) Dosing: Once weekly injection Average weight loss: 15-22% of body weight FDA approved: 2022 (Mounjaro), 2023 (Zepbound) Most effective weight loss medication available What Makes Tirzepatide Different: Tirzepatide activates two hormone receptors instead of one: GLP-1 Effects (same as semaglutide): Appetite suppression Slowed stomach emptying Increased insulin secretion Reduced glucagon production Plus GIP Effects: Enhanced insulin response Improved insulin sensitivity Effects on fat metabolism Additional appetite suppression Result: 5-7% more weight loss than semaglutide alone, making tirzepatide the most effective option
Each batch is produced using controlled manufacturing procedures designed to support identity, consistency, formulation accuracy, and reproducibility for laboratory research
The hazard ratios (HRs) and confidence intervals (CIs) were calculated using a stratified Cox proportional hazards model in which treatment was considered a fixed effect and trial-level cardiovascular risk as the stratification factor
R.KangG
